Sept 18 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO :
* CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO MOB-015 FROM MOBERG PHARMA FOR THE TOPICAL TREATMENT OF ONYCHOMYCOSIS
* CIPHER PHARMACEUTICALS - MOBERG WILL RECEIVE AN UPFRONT PAYMENT OF $0.5 MILLION, ELIGIBLE FOR $14.1 MILLION IN DEVELOPMENT AND REGULATORY MILESTONES
* CIPHER PHARMACEUTICALS INC - AGREEMENT ALSO INCLUDES ROYALTIES FROM NET PRODUCT SALES IN CANADA
* CIPHER PHARMACEUTICALS - AGREEMENT PROVIDES MOBERG WILL BE RESPONSIBLE FOR MANUFACTURING AND SUPPLYING FINISHED PRODUCT TO CIPHER